Masimo (NASDAQ:MASI) Price Target Raised to $201.00

Share on StockTwits

Masimo (NASDAQ:MASI) had its target price increased by Needham & Company LLC from $182.00 to $201.00 in a research note issued to investors on Thursday morning, BenzingaRatingsTable reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

A number of other brokerages have also weighed in on MASI. UBS Group upped their target price on shares of Masimo from $190.00 to $207.00 and gave the stock a buy rating in a research note on Thursday. Piper Sandler reaffirmed a buy rating and issued a $175.00 target price on shares of Masimo in a research note on Wednesday, January 15th. BidaskClub raised shares of Masimo from a buy rating to a strong-buy rating in a research report on Wednesday, January 22nd. Finally, Piper Jaffray Companies reissued an overweight rating and set a $175.00 price target (up from $161.00) on shares of Masimo in a research report on Tuesday, December 17th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $177.36.

Shares of NASDAQ MASI opened at $178.37 on Thursday. The firm has a market cap of $9.51 billion, a PE ratio of 51.85, a PEG ratio of 2.18 and a beta of 1.11. Masimo has a 1-year low of $118.93 and a 1-year high of $186.91. The company has a fifty day moving average price of $171.39 and a 200 day moving average price of $156.20.

Masimo (NASDAQ:MASI) last announced its earnings results on Wednesday, February 19th. The medical equipment provider reported $0.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.04. The firm had revenue of $247.51 million during the quarter, compared to analyst estimates of $243.79 million. Masimo had a net margin of 20.92% and a return on equity of 17.03%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.83 EPS. Analysts expect that Masimo will post 3.56 earnings per share for the current fiscal year.

In other news, Director Sanford Fitch sold 7,000 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $156.27, for a total value of $1,093,890.00. Following the sale, the director now directly owns 51,245 shares of the company’s stock, valued at approximately $8,008,056.15. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Micah W. Young sold 8,401 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $170.01, for a total transaction of $1,428,254.01. Following the completion of the sale, the chief financial officer now directly owns 8,401 shares in the company, valued at $1,428,254.01. The disclosure for this sale can be found here. Insiders have sold a total of 57,378 shares of company stock worth $9,435,640 over the last three months. Insiders own 11.50% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Flagship Harbor Advisors LLC grew its position in shares of Masimo by 45.7% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 236 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 74 shares in the last quarter. Louisiana State Employees Retirement System grew its position in shares of Masimo by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 11,900 shares of the medical equipment provider’s stock worth $1,881,000 after purchasing an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its position in shares of Masimo by 1.1% during the 4th quarter. Municipal Employees Retirement System of Michigan now owns 9,100 shares of the medical equipment provider’s stock worth $1,438,000 after purchasing an additional 100 shares in the last quarter. Stone Ridge Asset Management LLC grew its position in shares of Masimo by 0.5% during the 4th quarter. Stone Ridge Asset Management LLC now owns 20,581 shares of the medical equipment provider’s stock worth $3,253,000 after purchasing an additional 100 shares in the last quarter. Finally, Utah Retirement Systems grew its position in shares of Masimo by 1.1% during the 4th quarter. Utah Retirement Systems now owns 9,021 shares of the medical equipment provider’s stock worth $1,426,000 after purchasing an additional 100 shares in the last quarter. 84.20% of the stock is currently owned by institutional investors.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Further Reading: Guidelines for Successful Channel Trading

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.